PF-AtlasClinical Trials › NCT00023465

Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging

FDG-PET · Not specified

Registry ID
NCT00023465
Phase
Not specified
Status
Unknown
Drug / intervention
FDG-PET
Sponsor
National Center for Research Resources (NCRR)
Enrollment
10
Locations
1

About this trial

It has been shown that neutrophils (a specific type of cell) are involved in inflammation in the lungs of CF patients. Neutrophil levels in CF patients have been measured by bronchoalveolar lavage (BAL), which samples cells in the fluid lining of the lungs. Other studies have measured neutrophil levels and inflammation in other parts of the body using PET scanning. This study aims to show that PET scanning can be used as a non-invasive marker of inflammation in the lungs of patients with CF, which would be a useful tool in treatment. The primary goal of this study is to draw a connection between the level of inflammation shown in the PET scan and the number of neutrophils obtained from the BAL. This study will also look at how the PET images relate to inflammatory molecules in the lungs and to the FEV-1 obtained through spirometry.

View NCT00023465 on ClinicalTrials.gov →

Explore related

Related trials

Medical disclaimer. This page summarizes public trial data for NCT00023465 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.